PDCD1 and urogenital neoplasm: The greatest risk of grade 3–4 PAEs in patients with urogenital cancer was related to anti-PDL1 plus targeted therapy drug, which had significant differences with the other interventions except for anti-PD1, anti-PD1 plus targeted therapy drug, and anti-PDL1 plus anti-CTLA4.